Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy

Antibodies against PD1 have been used to treat progressive multifocal leukoencephalopathy (PML), a rare brain disease caused by JC virus. We used these antibodies (nivolumab) to treat PML in 3 kidney transplant recipients. All died within 8 weeks of diagnosis. Hence, nivolumab did not improve PML ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Medrano, Chloé, Vergez, François, Mengelle, Catherine, Faguer, Stanislas, Kamar, Nassim, Del Bello, Arnaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2019
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810212/
https://www.ncbi.nlm.nih.gov/pubmed/31625858
http://dx.doi.org/10.3201/eid2511.190705
_version_ 1783462194924486656
author Medrano, Chloé
Vergez, François
Mengelle, Catherine
Faguer, Stanislas
Kamar, Nassim
Del Bello, Arnaud
author_facet Medrano, Chloé
Vergez, François
Mengelle, Catherine
Faguer, Stanislas
Kamar, Nassim
Del Bello, Arnaud
author_sort Medrano, Chloé
collection PubMed
description Antibodies against PD1 have been used to treat progressive multifocal leukoencephalopathy (PML), a rare brain disease caused by JC virus. We used these antibodies (nivolumab) to treat PML in 3 kidney transplant recipients. All died within 8 weeks of diagnosis. Hence, nivolumab did not improve PML outcome after solid organ transplantation.
format Online
Article
Text
id pubmed-6810212
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-68102122019-11-01 Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy Medrano, Chloé Vergez, François Mengelle, Catherine Faguer, Stanislas Kamar, Nassim Del Bello, Arnaud Emerg Infect Dis Research Letter Antibodies against PD1 have been used to treat progressive multifocal leukoencephalopathy (PML), a rare brain disease caused by JC virus. We used these antibodies (nivolumab) to treat PML in 3 kidney transplant recipients. All died within 8 weeks of diagnosis. Hence, nivolumab did not improve PML outcome after solid organ transplantation. Centers for Disease Control and Prevention 2019-11 /pmc/articles/PMC6810212/ /pubmed/31625858 http://dx.doi.org/10.3201/eid2511.190705 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research Letter
Medrano, Chloé
Vergez, François
Mengelle, Catherine
Faguer, Stanislas
Kamar, Nassim
Del Bello, Arnaud
Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy
title Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy
title_full Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy
title_fullStr Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy
title_full_unstemmed Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy
title_short Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy
title_sort effectiveness of immune checkpoint inhibitors in transplant recipients with progressive multifocal leukoencephalopathy
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810212/
https://www.ncbi.nlm.nih.gov/pubmed/31625858
http://dx.doi.org/10.3201/eid2511.190705
work_keys_str_mv AT medranochloe effectivenessofimmunecheckpointinhibitorsintransplantrecipientswithprogressivemultifocalleukoencephalopathy
AT vergezfrancois effectivenessofimmunecheckpointinhibitorsintransplantrecipientswithprogressivemultifocalleukoencephalopathy
AT mengellecatherine effectivenessofimmunecheckpointinhibitorsintransplantrecipientswithprogressivemultifocalleukoencephalopathy
AT faguerstanislas effectivenessofimmunecheckpointinhibitorsintransplantrecipientswithprogressivemultifocalleukoencephalopathy
AT kamarnassim effectivenessofimmunecheckpointinhibitorsintransplantrecipientswithprogressivemultifocalleukoencephalopathy
AT delbelloarnaud effectivenessofimmunecheckpointinhibitorsintransplantrecipientswithprogressivemultifocalleukoencephalopathy

Ejemplares similares